StreetInsider.com News Articles

Sangamo launches auction for pain program amid Chapter 11 proceedings

Tue, 13 Oct 2026 16:01:53 -0400

Sangamo Therapeutics, Inc. (OTCID Basic Market: SGMOQ) has initiated an auction process for its ST-503 program, a clinical-stage investigational treatment for chronic neuropathic pain caused by small fiber neuropathy (SFN). The auction is expected to conclude in the fourth quarter of 2026, according to a press release from the company.

ST-503 uses an adeno-associated virus vector to deliver an engineered zinc finger repressor designed to reduce expression of SCN9A, the gene encoding the Nav1.7 sodium channel involved in pain signaling. Seven sites have been activated in the Phase 1/2 STAND study evaluating the treatment's safety and efficacy. The U.S. Food and

Sangamo launches auction for pain program amid Chapter 11 proceedings

Tue, 13 Oct 2026 16:01:53 -0400

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

Tue, 13 Oct 2026 16:01:00 -0400

Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026

Previously announced asset sale transactions with PTC and Lilly have closed, generating $163.55 million in gross cash proceeds

RICHMOND, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCID Basic Market: SGMOQ) today announced the new timeline for its continued sale process for the ST-503 program, a clinical-stage investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN).

Seven sites have been activated in the Phase

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

Tue, 13 Oct 2026 16:01:00 -0400

Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026

Previously announced asset sale transactions with PTC and Lilly have closed, generating $163.55 million in gross cash proceeds

Seven sites have been activated in the Phase

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

Tue, 13 Oct 2026 16:01:00 -0400

Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026

Previously announced asset sale transactions with PTC and Lilly have closed, generating $163.55 million in gross cash proceeds

Seven sites have been activated in the Phase

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

Tue, 13 Oct 2026 16:01:00 -0400

Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026

Previously announced asset sale transactions with PTC and Lilly have closed, generating $163.55 million in gross cash proceeds

Seven sites have been activated in the Phase

Sangamo picks Lilly and PTC as buyers in bankruptcy auction

Wed, 12 Aug 2026 16:01:43 -0400

Sangamo Therapeutics (OTCID Basic Market: SGMOQ) has selected winning bidders in a court-supervised auction under Section 363 of the U.S. Bankruptcy Code, yielding approximately $163.55 million in cash at closing and up to $100 million in potential future milestone payments, according to a press release.

PTC Therapeutics was selected as the winning bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec (ST-920), for $111 million in cash at closing. The deal includes up to $100 million in potential milestone payments: $80 million upon receiving accelerated FDA approval and $20 million upon full or traditional FDA approval.

Eli Lilly and Company was selected to

Sangamo picks Lilly and PTC as buyers in bankruptcy auction

Wed, 12 Aug 2026 16:01:43 -0400

Eli Lilly and Company was selected to

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

RICHMOND, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCID Basic Market: SGMOQ), a genomic medicine company, today announced that it has successfully concluded a court-supervised auction process under Section 363 of the U.S. Bankruptcy Code to maximize the value of Sangamo’s assets for the benefit of all stakeholders.

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive